MedTrace Logo

Probiotics for Prevention of Ventilator-Associated Pneumonia (VAP)

NCT01301131 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2012-01-02

No results posted yet for this study

Summary

Hospitalized patients with ventilator are randomized to receive fermented dairy product containing L. casei shirota or nothing. The main outcome is development of ventilator-associated pneumonia (VAP)

Conditions

  • Drug Safety

Interventions

OTHER

Probiotics

80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily

OTHER

control

usual oral care

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Visanu Thamlikitkul, MD · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-08-31
Completion
2013-10-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301131 on ClinicalTrials.gov